| Phase 14 trials |
|
Phase 1
|
NCT04855292 |
Jul 2021 → Dec 2022 |
diabetes mellitus |
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04839744 |
May → Jun 2021 |
— |
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04790006 |
Apr 2021 → Mar 2022 |
type 2 diabetes mellitus |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT03990090 |
Jul 2019 → Nov 2020 |
— |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 24 trials |
|
Phase 2
|
NCT06226090 |
Feb → Sep 2024 |
obesity disorder |
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT05348122 |
Jun 2022 → Nov 2023 |
type 2 diabetes mellitus |
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT05299697 |
May 2022 → Jun 2023 |
obesity disorder |
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT05063253 |
Oct 2021 → Mar 2024 |
type 2 diabetes mellitus |
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. |
Unknown
|
No outcome recorded
|
| Phase 33 trials |
|
Phase 3
|
NCT06258148 |
Apr 2024 → Jan 2026 |
type 2 diabetes mellitus |
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT06235086 |
Apr 2024 → Feb 2026 |
type 2 diabetes mellitus |
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT05997576 |
Nov 2023 → Feb 2025 |
obesity disorder |
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. |
Completed
|
No outcome recorded
|